- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Biocon Limited — Updates, 07-04-2026: Press Release
07-04-2026 | 04:07 pm
07-04-2026 | 04:07 pm
Biocon commercially launched Bosaya™ and Aukelso™, denosumab biosimilars, in the U.S. These address osteoporosis and cancer-related bone issues in a ~$5 billion market, significantly expanding Biocon's portfolio.
No comments yet. Be the first to comment!